Last reviewed · How we verify

NCT06855056: PROSPECT

Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

Recruiting now Last updated 6 August 2025
What this trial tests

trial in Liver Cirrhosis in 189 participants. Currently enrolling.

Timeline
1 March 2025
Primary endpoint
30 March 2026
30 September 2026

Quick facts

Lead sponsorEuropean Foundation for Study of Chronic Liver Failure
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment189
Start date1 March 2025
Primary completion30 March 2026
Estimated completion30 September 2026
Sites9 locations across France, Italy, United Kingdom, Germany, Spain

Conditions studied

Sponsor

European Foundation for Study of Chronic Liver Failure

Who can join

Adults 18 to 80, any sex, with Liver Cirrhosis or Decompensated Cirrhosis of Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the disease

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Cirrhosis

Currently open trials in the same condition.

Other European Foundation for Study of Chronic Liver Failure trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06855056.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing